ECT Pulse Amplitude and Medial Temporal Lobe Engagement

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

62 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-10-31

Study Completion Date

2020-03-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Electroconvulsive therapy (ECT) remains the gold-standard treatment for patients with depressive episodes. During a typical four-week ECT series, most depressive episodes will respond to treatment and people will improve their level of functioning (return to work or family). Independent of the antidepressant effect of ECT, many patients experience transient memory impairment. This investigation will examine the impact of one ECT parameter (pulse amplitude or current) on brain changes (structure of connections within the brain) and clinical outcomes. The goal of this investigation is to determine the optimal parameter for an individual patient that will maintain the clinical response (reduce depression severity) and minimize side effects (eliminate memory issues related to treatment).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Electroconvulsive Therapy Amplitude Titration

NCT04621786

Major Depressive Disorder

COMPLETED NA

Amplitude Titration to Improve ECT Clinical Outcomes

NCT05699226

Depression ECT Cognitive Change

RECRUITING NA

Efficacy and Safety of Low Amplitude Electroconvulsive Therapy

NCT02351843

Depression

TERMINATED NA

The Antidepressant Effect of Repetitive Transcranial Magnetic Stimulation (rTMS)Compared to ECT

NCT00299403

Depressive Disorder

COMPLETED PHASE2/PHASE3

Comparing the Effects of Four Types of Electroconvulsive Therapy on Mood and Thinking in People With Depression

NCT00487500

Depression

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Electroconvulsive therapy (ECT) remains the gold-standard treatment for patients with depressive episodes. During a typical four-week ECT series, most depressive episodes remit, and formerly suicidal or psychotically depressed patients will resume their premorbid levels of functioning. Independent of the antidepressant effect of ECT, many patients experience debilitating but transient cognitive effects such as attention and memory deficits. These unwanted side effects are particularly troubling for older patients who are more likely to have existing cognitive deficits. Both the stimulus delivery (electrode placement, pulse amplitude, and pulse width) and seizure induction appear to work in synergy, but the underlying mechanism of action for successful response has yet to be fully elucidated. Moreover, further work is needed to understand the relationship between clinical improvement and cognitive impairment. This investigation will examine the clinical and neurocognitive impact of targeted medial temporal lobe engagement as a function of pulse amplitude, one of several variable factors influencing the ECT charge. The ECT charge is measured in millicoulombs (mC) and derived from multiplying pulse train duration, pulse-pair frequency, pulse width, and pulse amplitude. Pulse amplitude determines the induced electric field strength in the brain and is presently fixed at 900 milliamperes (mA) with no clinical or scientific justification. The central hypothesis of this investigation is that the optimal pulse amplitude for an individual patient will enhance neuroplasticity (clinical response) while minimizing the disruption of dominant hemisphere hippocampal cognitive circuitry (resulting in cognitive stability). The preliminary data informs the dosage range between 600 and 800 mA. Pulse amplitudes outside of this range compromise efficacy (500 mA) or may increase risk of cognitive impairment (900 mA). The first aim of this investigation will identify the electric field strength and neuroplasticity associated with clinical response. Critically, this aim will establish the neuroplasticity threshold, which is defined as the electric field strength necessary to induce neuroplasticity. The second aim will detect the neural correlates of ECT-mediated cognitive changes, which may be related to disrupted dominant hemisphere long-term potentiation. The third aim will use data-driven dual regression to predict the optimal pulse amplitude for an individual patient. This contribution will be significant because the electric field, when manipulated by pulse amplitude, can subsequently maximize hippocampal neuroplasticity (efficacy) and minimize disrupted connectivity (cognitive stability) thus improving clinical outcomes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depressive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Subjects randomized to right unilateral ECT with 600, 700, or 800 mA pulse amplitude.

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Double-blind (participant and outcomes assessor)

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

600 mA Right Unilateral ECT

MECTA Spectrum 5000Q Amplitude

Group Type EXPERIMENTAL

MECTA Spectrum 5000Q Amplitude

Intervention Type DEVICE

Current

700 mA Right Unilateral ECT

MECTA Spectrum 5000Q Amplitude

Group Type EXPERIMENTAL

MECTA Spectrum 5000Q Amplitude

Intervention Type DEVICE

Current

800 mA Right Unilateral ECT

MECTA Spectrum 5000Q Amplitude

Group Type ACTIVE_COMPARATOR

MECTA Spectrum 5000Q Amplitude

Intervention Type DEVICE

Current

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MECTA Spectrum 5000Q Amplitude

Current

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Diagnosis of major depressive disorder (with or without psychotic features)
2. the clinical indications for ECT including treatment resistance or a need for a rapid and definitive response
3. Hamilton Depression Rating Scale 24-item (HDRS-24) \> 21
4. age range between 50 and 80 years of age
5. right-handedness

Exclusion Criteria

1. Defined neurological or neurodegenerative disorder (e.g., history of head injury with loss of consciousness \> 5 minutes, epilepsy, Alzheimer's disease)
2. other psychiatric conditions (e.g., schizophrenia, schizoaffective disorder, bipolar disorder)
3. current drug or alcohol use disorder, except for nicotine; and 4) contraindications to MRI.

Minimum Eligible Age

50 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No